Stocks and Investing
Stocks and Investing
Wed, May 3, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Ed Arce Reiterated (AUPH) at Strong Buy and Held Target at $14 on, May 3rd, 2023
Ed Arce of HC Wainwright & Co., Reiterated "Aurinia Pharmaceuticals Inc." (AUPH) at Strong Buy and Held Target at $14 on, May 3rd, 2023.
Ed has made no other calls on AUPH in the last 4 months.
There is 1 other peer that has a rating on AUPH. Out of the 1 peers that are also analyzing AUPH, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Douglas Miehm of "RBC Capital" Reiterated at Buy and Held Target at $11 on, Thursday, February 23rd, 2023
Contributing Sources